Author

Zenaida Reynoso Mojares

Observed names: Zenaida Mojares, Zenaida R. Mojares

Observed institutions: International Vaccine Institute, Seoul National University, Takeda (Switzerland), GlaxoSmithKline (Italy)

ORCID: 0000-0003-1632-9268

Observed ORCID: 0000-0003-1632-9268

OpenAlex ID: A5032223866

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

2021 · Ganesh Kumar Rai, Tarun Saluja, et al. · The Lancet Infectious Diseases · 34

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

2023 · Vianney Tricou, Susannah Eyre, et al. · Vaccine · 31

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly

2019 · Sharon E Frey, Sepehr Shakib, et al. · Open Forum Infectious Diseases · 17

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics

2021 · Andrea Haekyung Haselbeck, Birkneh Tilahun Tadesse, et al. · Vaccines · 14

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

2018 · Nan-Chang Chiu, Li-Min Huang, et al. · Human Vaccines & Immunotherapeutics · 14

Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults

2018 · Phirangkul Kerdpanich, Pornthep Chanthavanich, et al. · PLoS neglected tropical diseases · 13

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

2022 · Maria Rosario Capeding, Birkneh Tilahun Tadesse, et al. · npj Vaccines · 11

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants

2022 · Tarun Saluja, Ganesh Kumar Rai, et al. · Vaccine · 8

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial

2022 · Yuan Liu, Lai Hock Tan, et al. · medRxiv · 3

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

2022 · Josefina Cadorna Carlos, Birkneh Tilahun Tadesse, et al. · The Lancet Regional Health - Western Pacific · 3

Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial

2024 · Renan James Lim, Xiangyan Qiu, et al. · Clinical and Experimental Vaccine Research · 1

Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study

2024 · Renan James Lim, Xiangyan Qiu, et al. · Clinical and Experimental Vaccine Research · 1

Works count: 12

Citation count: 150

H-index: 8

I10-index: 7